vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是WSFS FINANCIAL CORP的1.4倍（$373.9M vs $275.3M），WSFS FINANCIAL CORP净利率更高（31.5% vs 7.3%，领先24.2%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 7.5%），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 1.7%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
PAHC vs WSFS — 直观对比
营收规模更大
PAHC
是对方的1.4倍
$275.3M
营收增速更快
PAHC
高出13.4%
7.5%
净利率更高
WSFS
高出24.2%
7.3%
两年增速更快
PAHC
近两年复合增速
1.7%
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $275.3M |
| 净利润 | $27.5M | $86.8M |
| 毛利率 | 35.5% | — |
| 营业利润率 | 13.5% | — |
| 净利率 | 7.3% | 31.5% |
| 营收同比 | 20.9% | 7.5% |
| 净利润同比 | 762.1% | 31.7% |
| 每股收益（稀释后） | $0.67 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $373.9M | $271.9M | ||
| Q3 25 | $363.9M | $270.5M | ||
| Q2 25 | $378.7M | $267.5M | ||
| Q1 25 | $347.8M | $256.1M | ||
| Q4 24 | $309.3M | $261.5M | ||
| Q3 24 | $260.4M | $267.7M | ||
| Q2 24 | $273.2M | $266.0M |
净利润PAHCWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $27.5M | $72.7M | ||
| Q3 25 | $26.5M | $76.4M | ||
| Q2 25 | $17.2M | $72.3M | ||
| Q1 25 | $20.9M | $65.9M | ||
| Q4 24 | $3.2M | $64.2M | ||
| Q3 24 | $7.0M | $64.4M | ||
| Q2 24 | $752.0K | $69.3M |
毛利率PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 35.5% | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 29.0% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 32.9% | — | ||
| Q3 24 | 32.1% | — | ||
| Q2 24 | 31.9% | — |
营业利润率PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 13.5% | 35.8% | ||
| Q3 25 | 14.1% | 37.3% | ||
| Q2 25 | 8.9% | 35.7% | ||
| Q1 25 | 9.6% | 34.0% | ||
| Q4 24 | 8.3% | 32.3% | ||
| Q3 24 | 6.8% | 31.9% | ||
| Q2 24 | 6.7% | 34.0% |
净利率PAHCWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 7.3% | 26.7% | ||
| Q3 25 | 7.3% | 28.3% | ||
| Q2 25 | 4.5% | 27.0% | ||
| Q1 25 | 6.0% | 25.7% | ||
| Q4 24 | 1.0% | 24.6% | ||
| Q3 24 | 2.7% | 24.1% | ||
| Q2 24 | 0.3% | 26.0% |
每股收益（稀释后）PAHCWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.67 | $1.33 | ||
| Q3 25 | $0.65 | $1.37 | ||
| Q2 25 | $0.43 | $1.27 | ||
| Q1 25 | $0.51 | $1.12 | ||
| Q4 24 | $0.08 | $1.08 | ||
| Q3 24 | $0.17 | $1.08 | ||
| Q2 24 | $0.02 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | — |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $2.7B |
| 总资产 | $1.4B | $22.1B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $74.5M | $1.7B | ||
| Q3 25 | $85.3M | — | ||
| Q2 25 | $77.0M | — | ||
| Q1 25 | $70.4M | — | ||
| Q4 24 | $67.1M | $1.2B | ||
| Q3 24 | $89.8M | — | ||
| Q2 24 | $114.6M | — |
总债务PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — |
股东权益PAHCWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $332.4M | $2.7B | ||
| Q3 25 | $311.7M | $2.8B | ||
| Q2 25 | $285.7M | $2.7B | ||
| Q1 25 | $266.0M | $2.7B | ||
| Q4 24 | $246.8M | $2.6B | ||
| Q3 24 | $258.5M | $2.7B | ||
| Q2 24 | $256.6M | $2.5B |
总资产PAHCWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.4B | $21.3B | ||
| Q3 25 | $1.4B | $20.8B | ||
| Q2 25 | $1.4B | $20.8B | ||
| Q1 25 | $1.3B | $20.5B | ||
| Q4 24 | $1.3B | $20.8B | ||
| Q3 24 | $966.3M | $20.9B | ||
| Q2 24 | $982.2M | $20.7B |
负债/权益比PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | — |
| 自由现金流经营现金流 - 资本支出 | $8.3M | — |
| 自由现金流率自由现金流/营收 | 2.2% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 0.70× | — |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $19.4M | $220.0M | ||
| Q3 25 | $9.3M | $121.5M | ||
| Q2 25 | $21.3M | $37.2M | ||
| Q1 25 | $43.2M | $8.7M | ||
| Q4 24 | $3.1M | $219.9M | ||
| Q3 24 | $12.6M | $3.1M | ||
| Q2 24 | $28.4M | $44.8M |
自由现金流PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | $8.3M | $213.6M | ||
| Q3 25 | $-4.5M | $120.3M | ||
| Q2 25 | $8.1M | $35.2M | ||
| Q1 25 | $35.4M | $6.3M | ||
| Q4 24 | $-4.7M | $205.6M | ||
| Q3 24 | $3.0M | $-489.0K | ||
| Q2 24 | $15.4M | $42.1M |
自由现金流率PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 78.6% | ||
| Q3 25 | -1.2% | 44.5% | ||
| Q2 25 | 2.1% | 13.2% | ||
| Q1 25 | 10.2% | 2.5% | ||
| Q4 24 | -1.5% | 78.6% | ||
| Q3 24 | 1.2% | -0.2% | ||
| Q2 24 | 5.6% | 15.8% |
资本支出强度PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 2.3% | ||
| Q3 25 | 3.8% | 0.5% | ||
| Q2 25 | 3.5% | 0.7% | ||
| Q1 25 | 2.2% | 0.9% | ||
| Q4 24 | 2.5% | 5.5% | ||
| Q3 24 | 3.7% | 1.4% | ||
| Q2 24 | 4.8% | 1.0% |
现金转化率PAHCWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.70× | 3.03× | ||
| Q3 25 | 0.35× | 1.59× | ||
| Q2 25 | 1.24× | 0.51× | ||
| Q1 25 | 2.07× | 0.13× | ||
| Q4 24 | 0.97× | 3.43× | ||
| Q3 24 | 1.81× | 0.05× | ||
| Q2 24 | 37.80× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
WSFS
暂无分部数据
